Early measles vaccination in bone marrow transplant recipients.

Abstract:

:Measles vaccination has been recommended after the second year following bone marrow transplant (BMT) in patients not receiving immunosuppressive drugs. During a measles outbreak, we vaccinated all patients after the first year of transplant, and conducted a prospective trial to evaluate safety, effectiveness and sustained immunity after early vaccination. Patients received attenuated virus vaccine between 9 and 18 months after BMT. A total of 51 patients were evaluated and 27 of them (52.9%) were receiving immunosuppressive drugs. Only mild adverse reactions were noted. Nine patients (17.6%) were susceptible (IgG< or =100 mIU/ml) at vaccination, and all seroconverted. In those immune at vaccination, a four-fold increase in measles IgG titers was found in one of 34 patients (2.9%) with specific IgG> or =200 mIU/ml compared to 14 of 17 (82.3%) with IgG<200 mIU/ml (P< 0.0001). Sustained immunity after 24 months was more likely to occur in patients with specific IgG levels< or =200 or > or =500 mIU/mL (83.4 and 100%, respectively) in comparison to patients with 200

journal_name

Bone Marrow Transplant

authors

Machado CM,de Souza VA,Sumita LM,da Rocha IF,Dulley FL,Pannuti CS

doi

10.1038/sj.bmt.1704878

subject

Has Abstract

pub_date

2005-04-01 00:00:00

pages

787-91

issue

8

eissn

0268-3369

issn

1476-5365

pii

1704878

journal_volume

35

pub_type

临床试验,杂志文章
  • Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.

    abstract::The treatment of established veno-occlusive disease (VOD) of the liver with tissue plasminogen activator (tPA) has been disappointing. In attempts to improve upon these results we identified a subgroup of patients with consistently elevated bilirubin levels who did not meet conventional criteria for VOD (Susp VOD) but...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702069

    authors: Schriber J,Milk B,Shaw D,Christiansen N,Baer M,Slack J,Tezcan H,Wetzler M,Herzig G

    更新日期:1999-12-01 00:00:00

  • Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia W

    abstract::Reduced-intensity conditioning (RIC) regimens have been widely used for allogeneic hematopoietic cell transplantation (HCT) in elderly patients. After the emergence of tyrosine kinase inhibitor (TKI), most patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) now achieve negativ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0951-0

    authors: Akahoshi Y,Nishiwaki S,Arai Y,Harada K,Najima Y,Kanda Y,Shono K,Ota S,Fukuda T,Uchida N,Shiratori S,Tanaka M,Tanaka J,Atsuta Y,Kako S

    更新日期:2020-07-01 00:00:00

  • Life after transplant: are we becoming high maintenance in AML?

    abstract::Allogeneic hematopoietic cell transplantation (allo-HCT) for patients with AML is increasingly able to impact the historically poor outcomes in this disease. Nonetheless, even with transplant, the rates of post-HCT relapse are unacceptably high, and remain a great challenge in the treatment of patients with AML. Maint...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2016.160

    authors: Brunner AM,Fathi AT,Chen YB

    更新日期:2016-11-01 00:00:00

  • The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow.

    abstract::Recent studies from this laboratory have shown that unmanipulated, MHC-mismatched allogeneic bone marrow (BM) engrafts and produces complete allogeneic chimerism when administered to recipient mice 8 days following lethal irradiation and reconstitution with T cell-depleted (TCD) syngeneic bone marrow. Host lymphopoiet...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chester CH,Sykes M,Sachs DH

    更新日期:1989-03-01 00:00:00

  • SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking.

    abstract::Over the past 15 years, SCT has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs). Mechanistic studies recently provided the proof-of-concept that restoration of immunological tolerance can be achieved by haematopoietic SCT in chronic autoimmunity through eradication of the pat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2014.251

    authors: Alexander T,Bondanza A,Muraro PA,Greco R,Saccardi R,Daikeler T,Kazmi M,Hawkey C,Simoes BP,Leblanc K,Fibbe WE,Moore J,Snarski E,Martin T,Hiepe F,Velardi A,Toubert A,Snowden JA,Farge D

    更新日期:2015-02-01 00:00:00

  • Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

    abstract::In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.193

    authors: Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

    更新日期:2014-12-01 00:00:00

  • Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.

    abstract::Data from human clinical trials and animal experiments have suggested that T lymphocytes in donor marrow help to facilitate engraftment after allogeneic bone marrow transplantation, possibly through a suppressive effect on the immunity of the recipient. In previous studies marrows from HLA-identical donors were treate...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Martin PJ,Hansen JA,Torok-Storb B,Moretti L,Press O,Storb R,Thomas ED,Weiden PL,Vitetta ES

    更新日期:1988-09-01 00:00:00

  • Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.

    abstract::Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702719

    authors: Lamparelli T,van Lint MT,Gualandi F,Raiola AM,Barbanti M,Sacchi N,Ficai G,Ghinatti C,Bregante S,Berisso G,Dominietto A,Di Grazia C,Bruno B,Sessarego M,Casarino L,Verdiani S,Bacigalupo A

    更新日期:2000-12-01 00:00:00

  • Introduction: current issues in high-dose chemotherapy and stem cell support.

    abstract::In the 1980s it became clear that low numbers of primitive hematopoietic cells were present in the peripheral bloodstream. Early clinical trials by investigators in the USA, Australia, and Germany demonstrated that these cells could be collected and reinfused to support high-dose chemotherapy procedures in patients ot...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1701667

    authors: Shea TC

    更新日期:1999-05-01 00:00:00

  • Rapid and automated processing of bone marrow grafts without Ficoll density gradient for transplantation of cryopreserved autologous or ABO-incompatible allogeneic bone marrow.

    abstract::The growing number of BMTs has increased interest in safe and standardized in vitro bone marrow processing techniques. We describe our experience with a rapid automated method for the isolation of mononuclear cells (MNC) from large volumes of bone marrow using a Fenwal CS-3000 cell separator without employing density ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schanz U,Gmür J

    更新日期:1992-12-01 00:00:00

  • Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.

    abstract::Invasive fungal infections (IFI) with substantial mortality constitute an increasing problem among BMT patients. From 1986 to 1996 148 children underwent BMT, and are included in a retrospective analysis of the incidence, risk factors and outcome of IFI. By histopathology or culture-proven IFI (Candida, 10; Aspergillu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702654

    authors: Hovi L,Saarinen-Pihkala UM,Vettenranta K,Saxen H

    更新日期:2000-11-01 00:00:00

  • Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.

    abstract::NK cells can exert potent anti-leukemia activity after either autologous or allogeneic BMT. However, in autologous blood or marrow transplant patients, NK cell number and/or function could be reduced, and also may vary according to the sampling site. In order to evaluate the hypothesis that blood or marrow grafts from...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Arbour S,Toupin S,Bélanger R,Gyger M,Hallé JP,Perreault C,Roy DC

    更新日期:1996-03-01 00:00:00

  • Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.

    abstract::Peripheral blood progenitor cell (PBPC) populations used for transplantation were analyzed for the presence of CD34+ cells, colony-forming cells (initial CFC), and long-term culture initiating cells (LTC-IC) cultured on irradiated stroma for 5 weeks. Thirty-eight leukapheresis products were studied from 11 patients wi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bender JG,Lum L,Unverzagt KL,Lee W,Van Epps D,George S,Coon J,Ghalie R,McLeod B,Kaizer H

    更新日期:1994-04-01 00:00:00

  • Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemia.

    abstract::A 12-year-old girl with Fanconi anaemia (FA) received a bone marrow transplant from her HLA-identical brother following conditioning with cyclophosphamide (20 mg/kg), thoraco-abdominal radiation (TAI) (4 Gy) and equine anti-thymocyte globulin (ATG) (90 mg/kg). Engraftment was delayed and initially tenuous, and was fol...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701855

    authors: Mital MK,Curtis A,Spencer V,Barge D,Skinner R

    更新日期:1999-07-01 00:00:00

  • Return of immunohematopoietic impairment a long time after murine syngeneic bone marrow transplantation.

    abstract::We have tested the immunologic status and hematologic parameters of mice 2 months (short-term survivors) or 18 months (long-term survivors) after lethal total body irradiation and syngeneic bone marrow transplantation (SBMT), and of normal mice of corresponding age. Long-term SBMT survivors showed significantly lowere...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Skórski T,Kawalec M,Ratajczak M,Szczylik C,Kawiak J

    更新日期:1990-11-01 00:00:00

  • Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.

    abstract::We evaluated a non-radiation containing preparative regimen for persons with myeloma receiving bone marrow (BM) or blood cell transplants. Twenty-three adults with advanced multiple myeloma (15 responsive to chemotherapy, 8 resistant) received cyclophosphamide 120 mg/kg and busulfan 14-16 mg/kg followed by the infusio...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Schiller G,Nimer S,Vescio R,Lieb G,Lee M,Gajewski J,Territo M,Berenson J

    更新日期:1994-07-01 00:00:00

  • Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

    abstract::In allo-stem cell transplantation (SCT), it is unclear whether donor-specific anti-HLA Abs (DSAs) can actually mediate graft rejection or if they are simply surrogate markers for the cellular immunity that causes graft rejection. Here, we first analyzed a case of cord blood allograft rejection in which DSA and cytotox...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.119

    authors: Hanajiri R,Murata M,Sugimoto K,Murase M,Sakemura R,Goto T,Watanabe K,Imahashi N,Terakura S,Ohashi H,Akatsuka Y,Kurahashi S,Miyamura K,Kiyoi H,Nishida T,Naoe T

    更新日期:2015-09-01 00:00:00

  • Bone marrow transplantation from unrelated donors: the Italian experience. GITMO, AIEOP and IBMDR.

    abstract::We report on 24 patients with leukemia (19 pts), congenital disorders (4 pts) or severe aplastic anemia (1 pt) who received bone marrow transplantation from unrelated volunteer donors in 8 Italian Institutions. All the donor/recipient pairs were serologically HLA-A,B,DR matched; MLR was non reactive in 21 out of 24 ca...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lanino E,Lamparelli T,Dini G,Alessandrino EP,Aversa F,Calori E,Medugno D,Garbarino L,Locatelli F,Marenco P

    更新日期:1993-01-01 00:00:00

  • Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.

    abstract::When allogeneic BMT is used for the treatment of leukemia, depletion of T cells from the donor BM to avoid GVHD may be accompanied by persistence of host cells and post-transplant relapse. In this report, a murine model of MHC-compatible BMT was used to show that delayed infusion of immunocompetent donor cells early a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Johnson BD,Drobyski WR,Truitt RL

    更新日期:1993-04-01 00:00:00

  • Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

    abstract::High-risk (HR) multiple myeloma (MM) has poor outcomes with conventional therapy. Tandem autologous-non-myeloablative (NMA) allogeneic stem cell transplantation (autologous stem cell transplantation (ASCT)-NMA allogeneic SCT) is potentially curative secondary to graft-versus-myeloma effect. We retrospectively analysed...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2017.37

    authors: Nair AP,Walker P,Kalff A,Bergin K,Hocking J,Avery S,Curtis DJ,Patil S,Das T,Klarica D,Morgan S,Muirhead J,Gorniak M,Reynolds J,Spencer A

    更新日期:2017-06-01 00:00:00

  • Large scale recovery and characterization of stromal cell-associated primitive haemopoietic progenitor cells from filter-retained human bone marrow.

    abstract::Bone marrow aspirates are composed of two cellular compartments, an abundant buffy coat suspension and a minor particulate fraction. The particulate fraction is routinely removed by filtration prior to transplantation in order to reduce the risk of embolism. This study shows that the filter-retained fraction includes ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701616

    authors: Blazsek I,Delmas Marsalet B,Legras S,Marion S,Machover D,Misset JL

    更新日期:1999-04-01 00:00:00

  • Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT.

    abstract::CY in combination with BU is a widely used conditioning regimen for haematopoietic SCT (HSCT). The aim of this study was to evaluate the pharmacokinetics (PK) of CY and its major metabolite 4-hydroxyCY (HCY) in patients with thalassemia undergoing HSCT. A total of 55 patients received BU (16 mg/kg) followed by CY (160...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.254

    authors: Balasubramanian P,Desire S,Panetta JC,Lakshmi KM,Mathews V,George B,Viswabandya A,Chandy M,Krishnamoorthy R,Srivastava A

    更新日期:2012-09-01 00:00:00

  • Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.

    abstract::Although infants with stage 4 neuroblastoma (NB) usually have a good prognosis, metastatic relapses after 1 year of age and amplification of the N-myc oncogene are established poor prognostic factors. In order to improve the survival of patients with such high-risk factors, we performed consolidation with a busulfan (...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702376

    authors: Valteau-Couanet D,Benhamou E,Vassal G,Stambouli F,Lapierre V,Couanet D,Lumbroso J,Hartmann O

    更新日期:2000-05-01 00:00:00

  • Effects of ICOSLG expressed in mouse hematological neoplasm cell lines in the GVL reaction.

    abstract::As a member of the B7 family, inducible co-stimulator ligand (ICOSLG) expressed on tumor cell has been reported to have an important role in tumor immunity. In this study, we sought to determine whether the expression of ICOSLG in mouse hematological malignancy cells influences GVL reaction after mouse allogeneic BMT....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.103

    authors: Wang B,Ma N,Cheng H,Zhou H,Qiu H,Yang J,Wang J

    更新日期:2013-01-01 00:00:00

  • Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells.

    abstract::Among the drugs used in conditioning regimens for stem cell transplantation, high-dose melphalan (HDM) plays an important role for both its strong myeloablative effect and for its favourable dose-response ratio. Here we report five cases of high frequency atrial fibrillation (AF) developing after HDM. Duration of the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701217

    authors: Olivieri A,Corvatta L,Montanari M,Brunori M,Offidani M,Ferretti GF,Centanni M,Leoni P

    更新日期:1998-05-01 00:00:00

  • Pulmonary infection with microsporidia after allogeneic bone marrow transplantation.

    abstract::Microsporidia are obligate, intracellular protozoal parasites that can be pathogenic in immunocompromised individuals. The majority of cases of microsporidiosis have been documented in patients with HIV, and only a few case reports exist of infection in solid organ transplant patients. We report the first case of pulm...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704327

    authors: Teachey DT,Russo P,Orenstein JM,Didier ES,Bowers C,Bunin N

    更新日期:2004-02-01 00:00:00

  • Value and affordability of CAR T-cell therapy in the United States.

    abstract::In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, ti...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/s41409-020-0956-8

    authors: Fiorenza S,Ritchie DS,Ramsey SD,Turtle CJ,Roth JA

    更新日期:2020-09-01 00:00:00

  • Intestinal obstruction caused by bezoar: a rare complication after bone marrow transplantation.

    abstract::Gastrointestinal complications are described frequently after preparation of patients for bone marrow transplantation (BMT). Two patients who underwent BMT developed complications due to gastrointestinal bezoars. One patient developed intestinal obstruction, which necessitated emergency surgery, and the other patient ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ben-Yehuda A,Ben-Yehuda-Salz D,Or R,Landau EH,Krausz MM

    更新日期:1989-01-01 00:00:00

  • Therapy decisions in leukemia.

    abstract::Complex factors determine how physicians select between alternative therapies. We conducted a survey of 352 leukemia experts to determine consensus regarding optimal treatment for leukemia and to identify factors correlated with therapy decisions. The study evaluated both general treatment policies and recommendations...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Atkinson KA,Horowitz MM,Sobocinski KA,Rimm AA,Bortin MM,Gale RP

    更新日期:1992-01-01 00:00:00

  • New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.

    abstract::Although most children with ALL can be cured by chemotherapy approaches, allogeneic hematopoietic cell transplant (HCT) therapy offers a better chance of cure to selected high-risk patients in first remission and most children who relapse. Although transplant-related mortality has decreased significantly in the past d...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2014.114

    authors: Pulsipher MA,Wayne AS,Schultz KR

    更新日期:2014-10-01 00:00:00